Oregon Medicaid targets expensive hepatitis drug

July 31, 2014 by Jonathan J. Cooper

(AP)—An Oregon Medicaid committee is expected to significantly scale back access to an effective—but expensive—new drug used to treat hepatitis C.

The decision on Thursday would allow only a narrow set of Medicaid patients to be treated with the $1,000-per-pill drug known as Sovaldi.

Medical experts on Oregon's pharmaceutical review committee question whether the drug is worth the . Oregon's guidelines would allow the drug to be used only for patients with later stages of who have been compliant with previous medical treatments and drug-free for at least six months. The drug could only be prescribed by a liver specialist.

Oregon is grappling with the issue a day after Illinois' Medicaid program put in place tight restrictions on the use of the drug.

Explore further: Medical groups question price of new hep C drug

Related Stories

Medical groups question price of new hep C drug

March 11, 2014
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer ...

$1,000 Sovaldi now hepatitis treatment of choice

July 29, 2014
(AP)—A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.

FDA advisers unanimously back J&J hepatitis C drug

October 24, 2013
An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

$1,000-a-pill Sovaldi jolts US health care system (Update)

June 17, 2014
The latest pill for hepatitis C sounds like a difficult choice. Sovaldi cures the liver-wasting disease in 9 of 10 patients, but treatment can cost more than $90,000.

EU nations join forces against 'exorbitant' hepatitis C drug: France

July 10, 2014
France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

Cure rate for experimental hepatitis C drug tops 95 percent

April 10, 2014
(HealthDay)—Researchers report that an experimental drug has cured more than 95 percent of patients infected with hepatitis C, including some who failed other treatments.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.